title: [Micronized purified flavonoid fraction in treatment of pelvic varicose veins].
abstract: Presented herein are the results of studying efficacy of micronized purified flavonoid fraction (MPFF) in treatment of pelvic varicose veins (PVV) using reference ray-tracing methods of study. We examined a total of 85 patients with PVV. Of these, 65 subjects were found to have isolated dilatation of pelvic venous plexuses (study group), and 20 were diagnosed as having combined dilation of gonadal veins and venous plexuses of the pelvis (control group). Besides clinical examination, the patients were subjected to ultrasonographic angioscanning (USAS) and emission computed tomography (ECT) of pelvic veins before treatment and 2, 6, 12, 24, 36 and 60 months after the beginning of phlebotrophic therapy. Based on the findings of the clinical and instrumental studies, it was determined that MPFF was most efficient in patients with isolated dilatation of uterine and parametrial veins. In this group of patients, pelvic pain and other symptoms of the disease disappeared completely and the clinical effect persisted for a long time (up to 6-9 months). In the control group, venotonic therapy had a positive effect which was less pronounced as compared to the control group, and pelvic pain reappeared in the nearest time (up to 3 weeks) after withdrawal of MPFF.
authors: S G
authors: SG
authors: Gavrilov
authors: A V
authors: AV
authors: Karalkin
authors: E P
authors: EP
authors: Moskalenko
authors: E S
authors: ES
authors: Beliaeva
authors: A M
authors: AM
authors: Ianina
authors: A I
authors: AI
authors: Kirienko
mesh_terms: D000328:Adult; D001682:Biological Availability; D004108:Dilatation, Pathologic / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D004145:Diosmin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D010147:Pain Measurement; D017699:Pelvic Pain / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010388:Pelvis / Q000098:blood supply / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed / Q000379:methods; D016896:Treatment Outcome; D014463:Ultrasonography / Q000379:methods; D014648:Varicose Veins / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014680:Veins / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D004145:Diosmin